Activity of Venetoclax in Relapsed or Refractory CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
Lancet Oncol 2024 Mar 08;[EPub Ahead of Print], AP Kater, Ö Arslan, F Demirkan, Y Herishanu, B Ferhanoglu, MG Diaz, B Leber, M Montillo, P Panayiotidis, D Rossi, A Skarbnik, A Tempescul, M Turgut, CH Mellink, AF van der Kevie-Kersemaekers, S Lanham, B Sale, L Del Rio, R Popovic, BJ Chyla, T Busman, V Komlosi, X Wang, K Sail, GE Pena, T Vizkelety, F ForconiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.